Research programme: monoclonal antibody therapeutics - Emergent Biosolutions
Alternative Names: Viral haemorrhagic fever therapeutics- Emergent BiosolutionsLatest Information Update: 28 Dec 2024
At a glance
- Originator Mapp Biopharmaceutical
- Developer Emergent BioSolutions
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral haemorrhagic fevers
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Viral-haemorrhagic-fevers in USA (IV)
- 26 Dec 2022 Early research development is ongoing USA (Mapp Biopharmaceutical pipeline, December 2022)
- 28 Jun 2021 No recent reports of development identified for research development in Viral-haemorrhagic-fevers in USA (IV)